Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5.
CLEOCIN vs CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours).
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic